Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Aug 7:2017:bcr2017221078.
doi: 10.1136/bcr-2017-221078.

GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis

Leonie C S De Vries  1   2 , Valerie J Ludbrook  3 , Kirsty J Hicks  3 , Geert R D'Haens  1
Affiliations
Case Reports

GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis

Leonie C S De Vries et al. BMJ Case Rep. .

Abstract

Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerative colitis (UC). Tofacitinib inhibits cytokine signalling through blockade of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). Adverse events including neutropenia and anaemia resulting from JAK2 inhibition have been observed in actively treated patients. By selectively targeting JAK1, such adverse events could be expected to be avoided. This open label study was designed to enrol 15 patients with UC, however the trial was discontinued after two inclusions due to safety concerns with the agent in a parallel trial for systemic lupus erythematosus. GSK2586184 was administered in two patients with moderate-to-severe UC. The JAK1 selective inhibitor GSK2586184 was well tolerated and induced clinical and endoscopic response in two patients with moderate-to-severe UC. In addition, treatment with GSK2586184 decreased histology scores and faecal calprotectin levels at early withdrawal.

Keywords: drugs: gastrointestinal system; inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LCSDV has received research funding from GlaxoSmithKline. VJL and KJH are employees of GlaxoSmithKline. GRD’H has served as speaker, consultant and principal investigator for Abbott/Abbvie, AM Pharma, Centocor/Jansen Biologics, Engene, Photopill, Setpoint, Novonordisk, MSD, UCB, Takeda, TEVA, Millenium, Boerhinger Ingelheim, Elan, Ferring, DrFALK Pharma, Shire, Cosmo, AstraZeneca, GlaxoSmithKLine and PDL.

Figures

Figure 1
Figure 1
(A) The Total Mayo score, ranging from 0 to 12 points, decreased in both patients after treatment with GSK2586184 (B) The Mayo individual sub-scores, stool frequency (0–4), rectal bleeding (0–4), physician's global assessment (0–4) and the Mayo endoscopic sub-score (0–3) decreased in both patients after treatment with GSK2586184. (C) The (UCEIS) (0-11) decreased in both patients after treatment. (D) Endoscopy images of patients 1 and 2, treated with decreased in both patients after treatment with GSK2586184 for 7 and 2 weeks, respectively. (E) Serum concentrations of GSK2586184 measured in patient 1 at baseline, at day 14 pre- and post-dose and at day 28 post-dose. UCEIS, Ulcerative Colitis Index of Severity.
Figure 2
Figure 2
(A) Faecal calprotectin levels decreased in both patients after treatment with GSK2586184. (B) Serum CRP primarily decreased in patient 2 after treatment with GSK2586184. In patient 1, CRP concentrations were low at baseline, the increase was caused by a nasopharyngitis. (C) The Geboes score, ranging from 0 to 5, decreased in biopsies both patients after treatment with GSK258618. (D) IBDQ scores, ranging from 32 to 224 points, improved after treatment with GSK2586184.
See this image and copyright information in PMC

References

    1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713–25. 10.1056/NEJMra1102942 - DOI - PubMed
    1. Feagan BG, Rutgeerts P, Sands BE, et al. . GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710. 10.1056/NEJMoa1215734 - DOI - PubMed
    1. Coskun M, Salem M, Pedersen J, et al. . Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res 2013;76:1–8. 10.1016/j.phrs.2013.06.007 - DOI - PubMed
    1. Sandborn WJ, Su C, Sands BE, et al. . OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017;376:1723–36. 10.1056/NEJMoa1606910 - DOI - PubMed
    1. Kuhrt D, Wojchowski DM. Emerging EPO and EPO receptor regulators and signal transducers. Blood 2015;125:3536–41. 10.1182/blood-2014-11-575357 - DOI - PMC - PubMed

Publication types

MeSH terms